TARS News and Press, Tarsus Pharmaceuticals Inc. From 07/25/23

2023-07-25 10:18:59 ET Gainers: Bullfrog AI ( BFRG ) +35% . Carmell Therapeutics ( CTCX ) +32% . Kiniksa Pharmaceuticals ( KNSA ) +21% . Galecto ( GLTO ) +18% . Akebia Therapeutics ( AKBA ) +16% . Losers: NeuroOne Med...

2023-07-25 08:22:48 ET NeuroOne Medical Technologies Corporation ( NMTC ) -35% . announces pricing of public offering of common stock . Stoke Therapeutics ( STOK ) -34% announces positive new safety & efficacy data from patients treated with STK-001 in the ...

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root cause of Demodex blepharitis and has demonstrated efficacy across multiple clinical me...

2023-07-20 14:04:17 ET Shares of Tarsus Pharmaceuticals (NASDAQ: TARS) were up more than 12% as of 12:30 p.m. on Thursday. The stock is up more than 53% so far this year. Tarsus is a clinical-stage biotech company that focuses on disorders with unmet needs, particularly eye ...

2023-07-20 10:23:14 ET Gainers: PainReform ( PRFX ) +55% . T2 Biosystems ( TTOO ) +19% . Inotiv ( NOTV ) +15% . Tarsus Pharmaceuticals ( TARS ) +14% . Nanobiotix ( NBTX ) +11% . Losers: Vir Biotechnology ( VIR ) ...

2023-07-10 04:56:16 ET Summary The new July 2023 selections are the current top positive/negative forensic stocks based on combined scores from four different forensic algorithms. Both the 2022 January Positive Forensic portfolio beat the S&P 500 by +6.59% and the Negative For...

IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a virtual event to...

IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chi...

2023-05-10 10:00:22 ET Tarsus Pharmaceuticals press release ( NASDAQ: TARS ): Q1 GAAP EPS of -$0.88. Revenue of $2.5M (+363.0% Y/Y). For further details see: Tarsus Pharmaceuticals GAAP EPS of -$0.88, revenue of $2.5M

Continuing to build market awareness through disease education and deploying commercial leadership in anticipation of TP-03 August 25, 2023 PDUFA Presented health economics data suggesting a costly and substantial burden of illness in patients with Demodex blepharitis Tarsus to ...